Revance Releases Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Aegis Capital Reiterates Buy on Revance Therapeutics (RVNC) Following 4Q Report
February 28, 2017 8:18 AM ESTAegis Capital reiterated a Buy rating and $28.00 price target on Revance Therapeutic (NASDAQ: RVNC) following the company's 4Q earnings report. Revance reiterated its prior guidance for cash burn of $102 to $112 mil for 2017.
Analyst Difei Yang commented, "Yesterday, Revance Therapeutics announced fourth quarter... More
Revance Therapeutics (RVNC) Misses Q4 EPS by 11c
February 27, 2017 4:14 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.95), $0.11 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.
2017 Financial Outlook
Revance reiterates its financial guidance provided in January 2017. Revance expects cash... More
